Samsung Bioepis launches Soliris biosimilar in Europe

  发布时间:2023-12-08 10:08:53   作者:玩站小弟   我要评论
Samsung Bioepis, a biosimilar developer under Samsung Group, said Thursday that the company has comp 。

Samsung Bioepis, a biosimilar developer under Samsung Group, said Thursday that the company has completed the launches of its hematology biosimilar Epysqli, a biosimilar close to Soliris, in three European countries, hoping to gain ground in the rare blood disease biosimilar market.

According to Samsung Bioepis, the company introduced Epysqli in Germany in July, and the biosimilar made its debut in Italy and Spain last month.

Samsung Bioepis is also preparing for Epysqli’s launch in France and the Netherlands within the year, the company said, adding that it is not planning on launching the biosimilar in other European countries beyond that.

Epysqli, a biosimilar close to Soliris (eculizumab), is a treatment for patients with paroxysmal nocturnal hemoglobinuria, a rare disease where red blood cells prematurely break apart.

PNH is a debilitating and often fatal disease, but can be treated with medication. However, the price of Soliris is around $500,000 per patient, per year, depending on a patient's weight. This price limits the treatment's accessibility and availability.

Soliris was originally developed by US-based Alexion Pharmaceuticals. But the rights to Soliris are currently owned by AsztraZeneca, which completed the acquisition of Alexion Pharmaceuticals in 2021.

“Samsung Bioepis is pleased that the company can increase the availability of the medication through its launches in Europe. The company will continue its efforts and contribute to unmet medical needs,” Samsung Bioepis said.

Samsung Bioepis’ Epysqli received marketing authorization from the European Commission in May, based on its phase 3 clinical trial conducted in eight countries between August 2019 and October 2021.

Adding Epysqli to its portfolio, Samsung Bioepis currently has seven biosimilars approved for use in Europe, including Benepali, an anti-inflammatory biosimilar close to Enbrel, and Imraldi, a biosimilar close to Humira.


  • Hanwha at forefront of Korea’s space leadership

    Hanwha Aerospace said Wednesday it plans to become a total services provider for outer space, rangin
  • 사전투표 D

    국민의힘 김태우 강서구청장 보궐선거 후보가 5일 강서구 방화동 모아타운 통합추진위 사무실 개소식에서 발언하고 있다. 연합뉴스강서구청장 보궐선거 사전투표를 하루 앞두고 김태우 국민의
  • [Photo News] AI, conventional painting come together

    Interdisciplinary artist Elly Cho's solo exhibition "Transcendent Echoes" will open Sunday at K
  • [From the scene] Eye

    This year’s Busan International Film Festival, which kicked off Oct. 4, invited a total of 269 movie
  • More webtoon

    More popular webtoon series are being adapted into live-action TV dramas with the return of actors a
  • [Korean History] 2002, when Korea soared through World Cup

    The dawn of the 21st century was not the brightest of days for South Korea, still hampered by the 19